董事
Fred A. Middleton is a corporate director and institutional venture capital investor with more than three decades of leadership experience in the biotechnology and biomedical industries.[[1]](https://theorg.com/org/calcimedica/org-chart/fred-middleton)[[2]](https://calcimedica.com/about-us/)[[3]](https://www.sec.gov/Archives/edgar/data/1534133/000119312526197104/ck0001534133-20251231.htm) He serves as a Director on the board of CalciMedica, Inc. (CALC), having joined the public company’s board at the time of its merger closing in March 2023 after previously serving on the board of private CalciMedica from May 2020.[[3]](https://www.sec.gov/Archives/edgar/data/1534133/000119312526197104/ck0001534133-20251231.htm)[[6]](https://ir.calcimedica.com/corporate-governance/board-of-directors/)[[7]](https://www.marketscreener.com/insider/FRED-MIDDLETON-A02R67/) In addition to his CalciMedica role, he is a long‑time Managing Director of Sanderling Ventures, where since 1987 he has invested in and helped build over 20–25 early‑stage biomedical ventures in the firm’s portfolios.[[1]](https://theorg.com/org/calcimedica/org-chart/fred-middleton)[[2]](https://calcimedica.com/about-us/)[[3]](https://www.sec.gov/Archives/edgar/data/1534133/000119312526197104/ck0001534133-20251231.htm)[[5]](https://opportunity.org/who-we-are/people/fred-middleton)
Over his career, Middleton has held senior operating and financial roles at pioneering life‑science companies, including serving as Chief Financial Officer and board member of Regeneron Pharmaceuticals, Inc. from 1991 to 2001 and as the third original member of Genentech’s management team, where he was CFO and led the biotech industry’s first successful IPO in 1980.[[1]](https://theorg.com/org/calcimedica/org-chart/fred-middleton)[[3]](https://www.sec.gov/Archives/edgar/data/1534133/000119312526197104/ck0001534133-20251231.htm)[[5]](https://opportunity.org/who-we-are/people/fred-middleton) He has founded or led investment platforms such as Morgan Stanley Ventures, an institutional fund focused on technology and biotech investments, and has served as chairman, CEO, or director for portfolio companies including Pacira Pharmaceuticals/Pacira BioSciences, Stereotaxis, ViaCyte, Endocyte, Chimerix, CardioNet, and Altor Biosciences.[[1]](https://theorg.com/org/calcimedica/org-chart/fred-middleton)[[3]](https://www.sec.gov/Archives/edgar/data/1534133/000119312526197104/ck0001534133-20251231.htm)[[5]](https://opportunity.org/who-we-are/people/fred-middleton) Middleton holds a B.S. in Chemistry from the Massachusetts Institute of Technology and an M.B.A. (with distinction) from Harvard Business School, and was elected to the MIT Corporation in 2007.[[1]](https://theorg.com/org/calcimedica/org-chart/fred-middleton)[[3]](https://www.sec.gov/Archives/edgar/data/1534133/000119312526197104/ck0001534133-20251231.htm)[[5]](https://opportunity.org/who-we-are/people/fred-middleton)
查看完整内部人档案 →